Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

(2013) H. Ali et al.   BMJ-British Medical Journal

Evidence of Human Papillomavirus Vaccine Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007–2010

(2012) Heidi M. Bauer et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance

(2012) Julia ML Brotherton et al.   Future Microbiology

Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer

(2012) Peng Guan et al.   INTERNATIONAL JOURNAL OF CANCER

Incidence of Genital Warts in Sweden Before and After Quadrivalent Human Papillomavirus Vaccine Availability

(2012) A. Leval et al.   JOURNAL OF INFECTIOUS DISEASES

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

(2012) S. N. Tabrizi et al.   JOURNAL OF INFECTIOUS DISEASES

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

(2012) John T. Schiller et al.   VACCINE

Human Papillomavirus Vaccine Introduction – The First Five Years

(2012) Lauri E. Markowitz et al.   VACCINE

Development and validation of reporting guidelines for studies involving data linkage

(2011) Megan A. Bohensky et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH

HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3

(2011) L. Baandrup et al.   GYNECOLOGIC ONCOLOGY

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

(2011) Julia ML Brotherton et al.   LANCET

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

(2011) Aimée R Kreimer et al.   LANCET ONCOLOGY

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

(2011) Dorota M. Gertig et al.   Sexual Health

Human Papillomavirus Genotypes in Cervical Intraepithelial Neoplasia Grade 3

(2010) P. E. Castle et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

(2010) Nubia Muñoz et al.   JNCI-Journal of the National Cancer Institute

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET